Structured evidence table for Kefir Gut Microbiome Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Kefir Gut Microbiome Randomized Trial | The risk of bias was assessed using Cochrane risk-of-bias tool and Risk of bias of non-randomized trials. | 1 | Hamsho M (2026) | Kefir: A Potential Gut Microbiota Modulator: A Systematic Review of Human Interventional Studies. |
| Kefir Gut Microbiome Randomized Trial | Kefir-specific bacterial species and strains were found in participants fecal samples suggesting colonization properties. | 1 | Hamsho M (2026) | Kefir: A Potential Gut Microbiota Modulator: A Systematic Review of Human Interventional Studies. |
| Kefir Gut Microbiome Randomized Trial | Kefir consumption was associated with modest and heterogenous changes in gut microbiota composition. | 1 | Hamsho M (2026) | Kefir: A Potential Gut Microbiota Modulator: A Systematic Review of Human Interventional Studies. |
| Kefir Gut Microbiome Randomized Trial | Kefir is a fermented dairy product containing live and active microbial culture, including lactic acid bacteria and yeast. | 1 | Hamsho M (2026) | Kefir: A Potential Gut Microbiota Modulator: A Systematic Review of Human Interventional Studies. |
| Kefir Gut Microbiome Randomized Trial | There is strong evidence of a correlation linking gut dysbiosis with reduced microbial diversity and a disruption in the balance of microbial communities, and inflammatory and metabolic disorders, including obesity and type 2 diabetes mellitus (T2DM) [,,]. | 3 | Alhaj Omar A. (2026) | Dairy Bioactive Compounds as Precision Modulators of Gut Microbiota: From Molecular Mechanisms to Personalized Immunometabolic Health |
| Kefir Gut Microbiome Randomized Trial | Meta-analyses of clinical interventions corroborate the results of regular yogurt or kefir intake, showing significant decreases in fasting glucose, low-density lipoprotein (LDL) cholesterol, and systemic C-reactive protein (CRP) in dysbiosis-associated conditions, with effect sizes dependent on strain composition, dose, and host genotype [,,,]. | 3 | Alhaj Omar A. (2026) | Dairy Bioactive Compounds as Precision Modulators of Gut Microbiota: From Molecular Mechanisms to Personalized Immunometabolic Health |
| Kefir Gut Microbiome Randomized Trial | 9 35 36 9 9 37 9 35 38 39 9 35 Figure 1 Despite the compelling evidence for the DB components as GM modulators, three critical knowledge gaps remain, including dose–response characterization, long-term clinical efficacy, and elucidation of the mechanism’s pathway [,,]. | 3 | Alhaj Omar A. (2026) | Dairy Bioactive Compounds as Precision Modulators of Gut Microbiota: From Molecular Mechanisms to Personalized Immunometabolic Health |
| Kefir Gut Microbiome Randomized Trial | 1 2 3 4 5 6 7 1 1 3 1 8 1 9 10 1 9 11 12 1 10 13 9 14 The GM is the complex community of Archaea, Bacteria, Eukarya, and viruses that live in the gastrointestinal tract in an intimate unit between the host and the microbes, called the holobiont [,]. | 3 | Alhaj Omar A. (2026) | Dairy Bioactive Compounds as Precision Modulators of Gut Microbiota: From Molecular Mechanisms to Personalized Immunometabolic Health |
Source documents